Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Zoetis/Jilin Guoyuan JV Gains China Approval for Swine Vaccine

publication date: Aug 5, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
A JV consisting of Zoetis, the recently spun-off animal health subsidiary of Pfizer, and Jilin Guoyuan Animal Health Co. has received marketing approval in China for a new swine vaccine. Rui Lan An™ targets highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). The JV, which was announced in 2011, will launch the vaccine immediately. Zoetis/Pfizer and Jilin Guoyuan formed the JV to meet the needs of China’s livestock producers, particularly the pork industry. More details....

Stock Symbols: (NYSE: ZTS) (NYSE: PFE)

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...